Omeros Corporation Reports Q1 2025 Financial Results

Omeros Corporation ( (OMER) ) has released its Q1 earnings. Here is a breakdown of the information Omeros Corporation presented to its investors.

Omeros Corporation is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for immunologic disorders, complement-mediated diseases, cancers, and addictive disorders. The company is known for its lead MASP-2 inhibitor, narsoplimab, which targets the lectin pathway of complement and is under FDA review for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy.

In its first-quarter 2025 earnings report, Omeros Corporation reported a net loss of $33.5 million, or $0.58 per share, an improvement from the $37.2 million loss in the same quarter of 2024. The company highlighted significant developments, including the FDA’s acceptance of its resubmitted Biologics License Application for narsoplimab and strategic financial maneuvers to manage its debt.

Key financial metrics include a decrease in cash and short-term investments to $52.4 million and a reduction in total operating expenses to $35.0 million from $39.0 million in the previous year. The company also reported a decrease in interest expense due to the repurchase of convertible notes, and a drop in OMIDRIA royalties, impacting its income from discontinued operations.

Strategically, Omeros is focusing its resources on the potential launch of narsoplimab and has paused certain programs to prioritize capital allocation. The company is also advancing its oncology platform and has established a steering committee to guide its acute myeloid leukemia program.

Looking ahead, Omeros Corporation is positioning itself to secure additional capital and is prioritizing the approval and launch of narsoplimab. The company is committed to advancing its core development priorities while managing its financial obligations effectively.